Get the Stockscreener App
0.8882
2.93%
-0.0268
After Hours:
.89
0.0018
+0.20%
Hoth Therapeutics Inc stock is traded at $0.8882, with a volume of 201.62K.
It is down -2.93% in the last 24 hours and down -11.18% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$0.915
Open:
$0.91
24h Volume:
201.62K
Relative Volume:
0.56
Market Cap:
$13.78M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.6729
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
-16.21%
1M Performance:
-11.18%
6M Performance:
-34.21%
1Y Performance:
-30.61%
1-Day Range:
$0.865
$0.9396
1-Week Range:
$0.865
$1.07
52-Week Range:
$0.6554
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.8882 | 14.20M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Risk Analysis: Can BSVN expand into new marketsMarket Activity Report & Verified Stock Trade Ideas - baoquankhu1.vn
Market Trends: Whats the outlook for Hoth Therapeutics Incs sectorGDP Growth & Verified Short-Term Plans - baoquankhu1.vn
Pharma News: What are the risks of holding Aduro Clean Technologies IncMarket Weekly Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Bear Alert: Can National Energy Services Reunited Corp Equity Warrant keep up with sector leaders2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Hoth reports positive interim results for cancer skin therapy By Investing.com - Investing.com Nigeria
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half - Benzinga
Hoth Therapeutics stock rises after positive interim trial results By Investing.com - Investing.com South Africa
Hoth Therapeutics stock rises after positive interim trial results - Investing.com
Hoth reports positive interim results for cancer skin therapy - Investing.com
Cancer patients on EGFR drugs report less toxicity and itch with HT-001 - Stock Titan
Hoth Therapeutics secures Chinese patent for cancer cell therapy By Investing.com - Investing.com Nigeria
Hoth Therapeutics gains after winning China patent for HT-KIT cancer program - MSN
Sell Signal: What’s the outlook for Hoth Therapeutics Inc.’s sector2025 Price Action Summary & Expert Verified Movement Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Hoth Therapeutics stock rises after securing Chinese patent for cancer therapy By Investing.com - Investing.com Australia
Hoth Therapeutics stock rises after securing Chinese patent for cancer therapy - Investing.com Nigeria
Hoth Therapeutics secures Chinese patent for cancer cell therapy - Investing.com
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position - PR Newswire
Aug Analyst Calls: Can Salarius Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Patterns & High Conviction Investment Ideas - baoquankhu1.vn
Why Hoth Therapeutics Inc. stock could outperform in 2025July 2025 Review & Low Drawdown Investment Strategies - bollywoodhelpline.com
3 Under-the-Radar Biotechs Under $5 That Could Soar 200% - MSN
Hoth Therapeutics highlights obesity and pipeline progress to regulators - TipRanks
Hoth Therapeutics, Inc. Presents New Drug Development Initiatives - TradingView — Track All Markets
Hoth Therapeutics receives positive EU regulatory decision for cancer trial By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Cancer trial to test topical drug for skin side effects from therapy - Stock Titan
Hoth Therapeutics receives positive EU regulatory decision for cancer trial - Investing.com
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing Ht-001 Oncology Trial Toward Multi-Country Site Activation - TradingView
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation - PR Newswire
Is Hoth Therapeutics Inc stock trending bullishPortfolio Performance Summary & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Published on: 2026-01-14 02:28:37 - baoquankhu1.vn
Gap Down: What Wall Street predicts for Hoth Therapeutics Inc stock priceJuly 2025 Technicals & Real-Time Buy Zone Alerts - Bộ Nội Vụ
Growth Value: Is Hoth Therapeutics Inc. stock supported by innovation pipelineEarnings Growth Report & Risk Managed Investment Signals - Улправда
Big Money Moves: Why Hoth Therapeutics Inc. stock could outperform in 2025Trade Analysis Summary & Fast Momentum Stock Entry Tips - ulpravda.ru
Why Hoth Therapeutics Inc. stock remains resilient2025 Momentum Check & Free Long-Term Investment Growth Plans - Улправда
Can Hoth Therapeutics Inc. stock weather global recessionWeekly Stock Report & Risk Controlled Daily Plans - Улправда
Will Hoth Therapeutics Inc. stock beat EPS estimatesJuly 2025 Spike Watch & Breakout Confirmation Trade Signals - Улправда
Volume Summary: Why Hoth Therapeutics Inc. stock could outperform in 2025Portfolio Return Report & Safe Capital Growth Tips - ulpravda.ru
Hoth Therapeutics Files Dual U.S. Provisional Patents to Expand Oncology Dermatology IP - Digital Health News
Hoth Therapeutics Files Two Provisional Patents To Build Oncology Dermatology Platform - Nasdaq
Hoth Therapeutics Files Two US Provisional Patents for Oncology-Focused Dermatology Platform; Shares Rise - marketscreener.com
Hoth Therapeutics Files New Patents to Expand Oncology Dermatology Platform - Contract Pharma
Hoth therapeutics files patents for oncology skin toxicity treatments By Investing.com - Investing.com Canada
Hoth Therapeutics stock rises after filing patents for cancer therapy skin toxicity treatments - Investing.com Nigeria
Hoth Therapeutics stock rises after filing patents for cancer therapy skin toxicity treatments By Investing.com - Investing.com South Africa
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):